UCB announced it will acquire Candid for $2.2B, placing a large bet on Candid’s antibody assets aimed at autoimmune diseases. The deal centers on a portfolio of bispecific and related biologic programs that UCB views as part of the next wave of immunological care. The transaction highlights how mid- and late-stage antibody platform strategies are being consolidated to accelerate pipeline buildouts in autoimmune indications, where demand for more targeted immunomodulation remains high. UCB’s move also signals continued investor and industry focus on bispecific mechanisms of action as developers seek deeper penetration of immunotherapy beyond oncology.